nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2024-5-106-110nnp-2390Research ArticleREVIEWSОБЗОРЫMuscle relaxers in acute musculoskeletal back painПрименение миорелаксантов при острой скелетно-мышечной боли в спинеhttps://orcid.org/0000-0002-0827-9427МухаметзяноваА. Х.MukhametzyanovaA. Kh.

Альбина Хамитовна Мухаметзянова - Кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского.

119021, Москва, ул. Россолимо, 11, стр. 1

Albina Khamitovna Mukhametzyanova - Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine.

11, Rossolimo St., Build. 1, Moscow 119021

albimukhametzyanova@yandex.ruhttps://orcid.org/0000-0003-4950-144XИсайкинА. И.IsaikinA. I.

Кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского.

119021, Москва, ул. Россолимо, 11, стр. 1

Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine.

11, Rossolimo St., Build. 1, Moscow 119021

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), MoscowRussian Federation202420102024165106110Copyright © Mukhametzyanova A.K., Isaikin A.I., 20242024Мухаметзянова А.Х., Исайкин А.И.Mukhametzyanova A.K., Isaikin A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2390

Treatment of patients with back pain is a global public health problem. The diagnosis of acute non-specific (musculoskeletal) back pain (ANBP) is made based on anamnestic data, results of somatic, neurological and neuroorthopaedic examinations, and exclusion of specific causes of back pain and discogenic radiculopathy. For ANBP, pharmacological treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and muscle relaxers (MR). Most modern clinical guidelines recommend non-benzodiazepine MR as the treatment of choice for ANBP. The results of randomized clinical trials have shown the efficacy and good tolerability of tolperisone (Mydocalm) as monotherapy and in combination with NSAIDs for ANBP. Tolperisone (Mydocalm) has analgesic properties and its main advantage over other MR is that it has no sedative effect.

Ведение пациентов с болью в спине является глобальной проблемой общественного здравоохранения. Диагноз острой неспецифической (скелетно-мышечной) боли в спине устанавливается на основании анамнестических данных, результатов соматического, неврологического и нейроортопедического осмотра, исключения специфических причин боли в спине, дискогенной радикулопатии. При острой неспецифической боли в спине фармакологическое лечение включает нестероидные противовоспалительные препараты (НПВП) и миорелаксанты. В большинстве современных клинических руководств небензодиазепиновые миорелаксанты рекомендованы в качестве препаратов выбора при острой скелетно-мышечной боли в спине. Результаты рандомизированных клинических исследований показали эффективность и хорошую переносимость толперизона (Мидокалма) в виде монотерапии и в комбинации с НПВП при неспецифической боли в спине. Толперизон (Мидокалм) обладает анальгетическими свойствами, а его основное преимущество перед другими миорелаксантами заключается в отсутствии седативного эффекта.

острая скелетно-мышечная боль в спинемиорелаксантыметоды леченияМидокалмacute musculoskeletal back painmuscle relaxerstreatment methodsMydocalmСтатья спонсируется компанией «Гедеон Рихтер»The article is sponsored by Gedeon RichterReferencesJames SL, Abate D, Abate KH, et al. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789-858. doi: 10.1016/S0140-6736(18)32279-7James SL, Abate D, Abate KH, et al. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789-858. doi: 10.1016/S0140-6736(18)32279-7Ferreira ML, de Luca K, Haile L, et al. Global, Regional, and National Burden of Low Back Pain, 1990–2020, Its Attributable Risk Factors, And Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e316-29. doi: 10.2139/ssrn.4318392Ferreira ML, de Luca K, Haile L, et al. Global, Regional, and National Burden of Low Back Pain, 1990–2020, Its Attributable Risk Factors, And Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e316-29. doi: 10.2139/ssrn.4318392Исайкин АИ, Насонова ТИ. Мышечный фактор в развитии скелетно-мышечной боли. Возможности терапии. Неврология, нейропсихиатрия, психосоматика. 2022;14(2):98-104. doi: 10.14412/2074-2711-2022-2-98-104Isaikin AI, Nasonova TI. Muscular factor in the development of musculoskeletal pain. Treatment options. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):98-104. doi: 10.14412/2074-2711-2022-2-98-104 (In Russ.).Itz CJ, Geurts JW, van Kleef M, Nelemans P. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain. 2013 Jan;17(1):5-15. doi: 10.1002/j.1532-2149.2012.00170.x. Epub 2012 May 28.Itz CJ, Geurts JW, van Kleef M, Nelemans P. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain. 2013 Jan;17(1):5-15. doi: 10.1002/j.1532-2149.2012.00170.x. Epub 2012 May 28.Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017 Feb 18;389(10070):736-47. doi: 10.1016/S01406736(16)30970-9. Epub 2016 Oct 11.Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017 Feb 18;389(10070):736-47. doi: 10.1016/S01406736(16)30970-9. Epub 2016 Oct 11.Парфенов ВА, Исайкин АИ. Боли в нижней части спины: мифы и реальность. Москва: ИМА-ПРЕСС; 2016. 104 с.Parfenov VA, Isaikin AI. Pain in the lower back: myths and reality. Moscow: IMA-PRESS; 2016. 104 p. (In Russ.).Koes BW, van Tulder M, Lin CW, et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010 Dec;19(12):2075-94. doi: 10.1007/s00586-0101502-y. Epub 2010 Jul 3.Koes BW, van Tulder M, Lin CW, et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010 Dec;19(12):2075-94. doi: 10.1007/s00586-0101502-y. Epub 2010 Jul 3.Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018 Nov;27(11):2791-803. doi: 10.1007/s00586018-5673-2. Epub 2018 Jul 3.Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018 Nov;27(11):2791-803. doi: 10.1007/s00586018-5673-2. Epub 2018 Jul 3.Парфенов ВА. Лечение острой неспецифической боли в спине, применение витаминов группы В. Неврология, нейропсихиатрия, психосоматика. 2022;14(6):98-102. doi: 10.14412/2074-2711-2022-6-98-102Parfenov VA. Treatment of acute non-specific back pain, the use of group B vitamins. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):98-102. doi: 10.14412/2074-2711-2022-6-98-102 (In Russ.).Chou R, Qaseem A, Snow V, et al. Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478-91. doi:10.7326/0003-4819-147-7-200710020-00006Chou R, Qaseem A, Snow V, et al. Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478-91. doi:10.7326/0003-4819-147-7-200710020-00006Исайкин АИ, Насонова ТИ, Мухаметзянова АХ. Эмоциональные нарушения и их терапия при хронической поясничной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):90-5. doi: 10.14412/2074-27112022-5-90-95Isaikin AI, Nasonova TI, Mukhametzyanova AKh. Emotional disorders and their therapy in chronic low back pain. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):90-5. doi: 10.14412/2074-2711-2022-590-95 (In Russ.).Головачева ВА, Головачева АА, Парфенов ВА. Ведение пациентов с подострой болью в спине: как эффективно предупредить хронизацию. Неврология, нейропсихиатрия, психосоматика. 2022;14(4):62-7. doi: 10.14412/2074-2711-2022-4-62-67Golovacheva VA, Golovacheva AA, Parfenov VA. Management of patients with subacute back pain: how to effectively prevent chronicity. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(4):62-7. doi: 10.14412/2074-2711-2022-4-62-67 (In Russ.).Парфенов ВА, Яхно НН, Кукушкин МЛ и др. Острая неспецифическая (скелетномышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2018;10(2):4-11. doi: 10.14412/2074-2711-2018-2-4-11Parfenov VA, Yakhno NN, Kukushkin ML, et al. Acute nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4-11. doi: 10.14412/2074-2711-2018-2-4-11 (In Russ.).Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7):514-30. doi: 10.7326/M16-2367. Epub 2017 Feb 14.Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7):514-30. doi: 10.7326/M16-2367. Epub 2017 Feb 14.Головачева АА, Головачева ВА, Парфенов ВА. Кинезиотерапия и нестероидные противовоспалительные препараты при неспецифической люмбалгии. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):89-96. doi: 10.14412/2074-2711-2022-1-89-96Golovacheva AA, Golovacheva VA, Parfenov VA. Kinesiotherapy and non-steroidal anti-inflammatory drugs for nonspecific lumbago. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):89-96. doi: 10.14412/2074-2711-2022-1-89-96 (In Russ.).Traeger AC, Hübscher M, Henschke N, et al. Effect of Primary Care-Based Education on Reassurance in Patients With Acute Low Back Pain: Systematic Review and Meta-analysis. JAMA Intern Med. 2015 May;175(5):733-43. doi: 10.1001/jamainternmed.2015.0217Traeger AC, Hübscher M, Henschke N, et al. Effect of Primary Care-Based Education on Reassurance in Patients With Acute Low Back Pain: Systematic Review and Meta-analysis. JAMA Intern Med. 2015 May;175(5):733-43. doi: 10.1001/jamainternmed.2015.0217Migliorini F, Maffulli N, Eschweiler J, et al. Non-steroidal anti-inflammatory drugs and gabapentinoids for chronic lumbar pain: a Bayesian network meta-analysis of randomized controlled trials. Br Med Bull. 2021 Jun 10;138(1):85-95. doi: 10.1093/bmb/ldab003Migliorini F, Maffulli N, Eschweiler J, et al. Non-steroidal anti-inflammatory drugs and gabapentinoids for chronic lumbar pain: a Bayesian network meta-analysis of randomized controlled trials. Br Med Bull. 2021 Jun 10;138(1):85-95. doi: 10.1093/bmb/ldab003Migliorini F, Vaishya R, Pappalardo G, et al. Between guidelines and clinical trials: evidence-based advice on the pharmacological management of non-specific chronic low back pain. BMC Musculoskelet Disord. 2023 May 30;24(1):432. doi: 10.1186/s12891-023-06537-0Migliorini F, Vaishya R, Pappalardo G, et al. Between guidelines and clinical trials: evidence-based advice on the pharmacological management of non-specific chronic low back pain. BMC Musculoskelet Disord. 2023 May 30;24(1):432. doi: 10.1186/s12891-023-06537-0Парфенов ВА, Прокопович ВС. Диагноз и лечение острой поясничной боли. Медицинский Совет. 2021;(10):60-5. doi: 10.21518/2079-701X-2021-10-60-65Parfenov VA, Prokopovich VS. Diagnosis and treatment of acute lumbar pain. Meditsinskiy sovet = Medical Council. 2021;(10):60-5. doi: 10.21518/2079-701X-2021-10-60-65 (In Russ.)].Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015 Mar 31;350:h1225. doi: 10.1136/bmj.h1225Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015 Mar 31;350:h1225. doi: 10.1136/bmj.h1225Van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003;2003(2):CD004252. doi: 10.1002/14651858.CD004252Van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003;2003(2):CD004252. doi: 10.1002/14651858.CD004252Abdel Shaheed C, Maher CG, Williams KA, McLachlan AJ. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis. Eur J Pain. 2017 Feb;21(2):228-37. doi: 10.1002/ejp.907. Epub 2016 Jun 22.Abdel Shaheed C, Maher CG, Williams KA, McLachlan AJ. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis. Eur J Pain. 2017 Feb;21(2):228-37. doi: 10.1002/ejp.907. Epub 2016 Jun 22.Chang WJ. Muscle Relaxants for Acute and Chronic Pain. Phys Med Rehabil Clin N Am. 2020 May;31(2):245-54. doi: 10.1016/j.pmr.2020.01.005. Epub 2020 Mar 13.Chang WJ. Muscle Relaxants for Acute and Chronic Pain. Phys Med Rehabil Clin N Am. 2020 May;31(2):245-54. doi: 10.1016/j.pmr.2020.01.005. Epub 2020 Mar 13.See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70.See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70.Табеева ГР. Миорелаксанты как альтернативные анальгетики в лечении неспецифической боли в спине. Неврология, нейропсихиатрия, психосоматика. 2017;9(2):89-94. doi: 10.14412/2074-27112017-2-89-94Tabeeva GR. Muscle relaxants as alternative analgesics in the treatment of nonspecific back pain. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2017;9(2):89-94. doi: 10.14412/20742711-2017-2-89-94 (In Russ.)].Low back pain management guideline. Philippine Academy of Rehabilitation Medicine. 2011. Available at: http://parm.com.ph/wp-content/uploads/2016/09/PARM-Low-Back-PainCPG-2011-1.pdfLow back pain management guideline. Philippine Academy of Rehabilitation Medicine. 2011. Available at: http://parm.com.ph/wp-content/uploads/2016/09/PARM-Low-Back-PainCPG-2011-1.pdfCanada TOP (2015). Evidence-informed primary care management of low back pain. Edmonton (AB): Toward Optimized Practice. Available at: http://www.topalbertadoctors.org/download/1885/LBPguideline.pdf?_201806250 85852Canada TOP (2015). Evidence-informed primary care management of low back pain. Edmonton (AB): Toward Optimized Practice. Available at: http://www.topalbertadoctors.org/download/1885/LBPguideline.pdf?_201806250 85852Guevara-Lopez U, Covarrubias-Gomez A, Elias-Dib J, et al; Consensus Group of Practice Parameters to Manage Low Back Pain. Practice guidelines for the management of low back pain. Consensus Group of Practice Parameters to Manage Low Back Pain. Cir Cir. 2011 MayJun;79(3):264-79, 286-302.Guevara-Lopez U, Covarrubias-Gomez A, Elias-Dib J, et al; Consensus Group of Practice Parameters to Manage Low Back Pain. Practice guidelines for the management of low back pain. Consensus Group of Practice Parameters to Manage Low Back Pain. Cir Cir. 2011 MayJun;79(3):264-79, 286-302.Latorre Marques E. The treatment of low back pain and scientific evidence. In: Norasteh AA, ed. Low back pain. InTech; 2012. P. 33-70. doi: 10.5772/33716Latorre Marques E. The treatment of low back pain and scientific evidence. In: Norasteh AA, ed. Low back pain. InTech; 2012. P. 33-70. doi: 10.5772/33716Pohjolainen T, Leinonen V, Franten J, et al. [Update on Current Care Guideline: Low back pain]. Duodecim. 2015;131(1):92-4 (In Finnish).Pohjolainen T, Leinonen V, Franten J, et al. [Update on Current Care Guideline: Low back pain]. Duodecim. 2015;131(1):92-4 (In Finnish).Van Wambeke P, Desomer A, Ailliet L, et al. Low back pain and radicular pain: assessment and management. KCE Report 287. Belgian Health Care Knowledge Centre. 2017. Available at: https://kce.fgov.be/sites/default/files/atoms/files/KCE_287_Low_back_pain_Report.pdfVan Wambeke P, Desomer A, Ailliet L, et al. Low back pain and radicular pain: assessment and management. KCE Report 287. Belgian Health Care Knowledge Centre. 2017. Available at: https://kce.fgov.be/sites/default/files/atoms/files/KCE_287_Low_back_pain_Report.pdfNational Institute for Health and Care Excellence. Low Back Pain and Sciatica in Over 16s: Assessment and Management. NICE. 2016. Available at: https://www.nice.org.uk/guidance/ng59National Institute for Health and Care Excellence. Low Back Pain and Sciatica in Over 16s: Assessment and Management. NICE. 2016. Available at: https://www.nice.org.uk/guidance/ng59Cashin AG, Folly T, Bagg MK, et al. Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. BMJ. 2021 Jul 7;374:n1446. doi: 10.1136/bmj.n1446Cashin AG, Folly T, Bagg MK, et al. Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. BMJ. 2021 Jul 7;374:n1446. doi: 10.1136/bmj.n1446Кукушкин МЛ, Брылев ЛВ, Ласков ВБ и др. Результаты рандомизированного двойного слепого параллельного исследования эффективности и безопасности применения толперизона у пациентов с острой неспецифической болью в нижней части спины. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(11):69-78. doi: 10.17116/jnevro201711711169-78Kukushkin ML, Brylev LV, Laskov VB, et al. Results of a randomized, double-blind, parallel study of the efficacy and safety of tolperisone in patients with acute nonspecific lower back pain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11):6978. doi: 10.17116/jnevro201711711169-78 (In Russ.).Вербицкая СВ, Парфенов ВА, Борисов КН. Толперизон (Мидокалм) в комплексной терапии острой поясничной боли. Клиническая фармакология и терапия. 2008;17(2):36-8. Доступно по ссылке: https://www.elibrary.ru/item.asp?id=11922560Verbitskaya SV, Parfenov VA, Borisov KN. Tolperisone (Mydocalm) in the complex therapy of acute low back pain. Klinicheskaya farmakologiya i terapiya. 2008;17(2):36-8. Available at: https://www.elibrary.ru/item.asp?id=11922560 (In Russ.)].Головачева ВА, Головачева АА, Зиновьева ОЕ и др. Толперизон в лечении острой и хронической неспецифической боли в спине. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):137-42. doi: 10.14412/2074-2711-2020-4-137-142Golovacheva VA, Golovacheva AA, Zinovyeva OE, et al. Tolperisone in the treatment of acute and chronic nonspecific back pain. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):137-42. doi: 10.14412/2074-2711-2020-4-137-142 (In Russ.).Quasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther. 2008 Summer;14(2):107-19. doi: 10.1111/j.1527-3458.2008.00044.xQuasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther. 2008 Summer;14(2):107-19. doi: 10.1111/j.1527-3458.2008.00044.xTekes K. Basic aspects of the pharmacodynamics of tolperisone, a widely applicable centrally acting muscle relaxant. Open Med Chem J. 2014 Jul 11;8:17-22. doi: 10.2174/1874104501408010017Tekes K. Basic aspects of the pharmacodynamics of tolperisone, a widely applicable centrally acting muscle relaxant. Open Med Chem J. 2014 Jul 11;8:17-22. doi: 10.2174/1874104501408010017Чиба Л, Жусупова АС, Лихачев СА и др. Систематический обзор по применению миорелаксантов при боли в нижней части спины. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(12):100-13. doi: 10.17116/jnevro2018118121100Csiba L, Zhussupova AS, Likhachev SA, et al. A systematic review of using myorelaxants in treatment of low back pain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12):100-13. doi: 10.17116/jnevro2018118121100 (In Russ.).Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled doubleblind trial. Pain. 1996 Oct;67(2-3):417-25. doi: 10.1016/0304-3959(96)03187-9Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled doubleblind trial. Pain. 1996 Oct;67(2-3):417-25. doi: 10.1016/0304-3959(96)03187-9Prabhoo R, Keny S, Prabhoo T, et al. A phase IV observational multi-centre, openlabel study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system. J Assoc Physicians India. 2011 Jan;59:33-7. Available at: https://www.semanticscholar.org/paper/Aphase-IV-observational-multi-centre,-openlabel-Prabhoo-Keny/5673085bc95aeea497e531316c53a22b88a46408Prabhoo R, Keny S, Prabhoo T, et al. A phase IV observational multi-centre, openlabel study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system. J Assoc Physicians India. 2011 Jan;59:33-7. Available at: https://www.semanticscholar.org/paper/Aphase-IV-observational-multi-centre,-openlabel-Prabhoo-Keny/5673085bc95aeea497e531316c53a22b88a46408Dulin J, Kovacs L, Ramm S, et al. Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 1998 Jul;31(4):137-42. doi: 10.1055/s-2007-979315Dulin J, Kovacs L, Ramm S, et al. Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 1998 Jul;31(4):137-42. doi: 10.1055/s-2007-979315Patat A, Klein MJ, Surjus A, et al. Effects of acute and repeated doses of two muscle relaxants chlormezanone and thiocolchicoside on vigilance and psychomotor performance of healthy volunteers. Hum Psychopharmacol. 1991;6:285-92. doi: 10.1002/hup.470060404Patat A, Klein MJ, Surjus A, et al. Effects of acute and repeated doses of two muscle relaxants chlormezanone and thiocolchicoside on vigilance and psychomotor performance of healthy volunteers. Hum Psychopharmacol. 1991;6:285-92. doi: 10.1002/hup.470060404Caron J, Kaye R, Wessel T, et al. An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine. J Clin Pharm Ther. 2020 Aug;45(4):77482. doi: 10.1111/jcpt.13165. Epub 2020 May 10.Caron J, Kaye R, Wessel T, et al. An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine. J Clin Pharm Ther. 2020 Aug;45(4):77482. doi: 10.1111/jcpt.13165. Epub 2020 May 10.Парфенов ВА, Богданов ЭИ, Ласков ВБ и др. Многоцентровое рандомизированное двойное слепое исследование эффективности и безопасности толперизона гидрохлорида пролонгированного высвобождения 450 мг (прием один раз в сутки) и толперизона гидрохлорида (Мидокалм®) 150 мг (прием три раза в сутки) при острой неспецифической боли в нижней части спины. Неврология, нейропсихиатрия, психосоматика. 2021;13(6):14-22. doi: 10.14412/20742711-2021-6-14-22Parfenov VA, Bogdanov EI, Laskov VB, et al. Multicenter, randomized, double-blind study of the efficacy and safety of prolonged release tolperisone hydrochloride 450 mg (Mydocalm® Long, once daily) and tolperisone hydrochloride 150 mg (three times daily) for acute non-specific lower back pain. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2021;13(6):14-22. doi: 10.14412/2074-2711-2021-6-14-22 (In Russ.).

The authors declare that there are no conflicts of interest present.